ES2323268T3 - Formulaciones de liberacion prolongada que contienen lamotrigina. - Google Patents
Formulaciones de liberacion prolongada que contienen lamotrigina. Download PDFInfo
- Publication number
- ES2323268T3 ES2323268T3 ES03766343T ES03766343T ES2323268T3 ES 2323268 T3 ES2323268 T3 ES 2323268T3 ES 03766343 T ES03766343 T ES 03766343T ES 03766343 T ES03766343 T ES 03766343T ES 2323268 T3 ES2323268 T3 ES 2323268T3
- Authority
- ES
- Spain
- Prior art keywords
- lamotrigine
- core
- pharmaceutically acceptable
- acceptable derivatives
- release formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 title abstract 5
- 229960001848 lamotrigine Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title 1
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 1
- 230000001815 facial effect Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una formulación de liberación prolongada, que comprende 1) un núcleo que comprende lamotrigina o uno de sus derivados farmacéuticamente aceptables; 2) una cubierta externa que recubre dicho núcleo, estando el espesor de dicha cubierta externa adaptado de tal forma que es sustancialmente impermeable a la entrada de fluido presente en el tracto gastrointestinal de un paciente y sustancialmente impermeable a la salida de lamotrigina o de uno de sus derivados farmacéuticamente aceptables, y 3) incluyendo dicha cubierta externa uno o más orificios que se extienden, de forma sustancialmente completa, desde el exterior del revestimiento a través de dicho revestimiento pero sin penetrar en dicho núcleo, permitiendo la liberación de lamotrigina o de uno de sus derivados farmacéuticamente aceptables desde el núcleo hasta el fluido presente en el tracto gastrointestinal de un paciente, teniendo dichos orificios una superficie o una superficie combinada de alrededor de 10 a alrededor de 60% del área facial de dicha formulación, 4) en la que la liberación de lamotrigina o de uno de sus derivados farmacéuticamente aceptables tiene lugar sustancialmente a través de dicho orificio y en la que la cubierta externa se disuelve cuando el pH excede de 5.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0217493A GB0217493D0 (en) | 2002-07-29 | 2002-07-29 | Novel methods of treatment |
| GB0217492A GB0217492D0 (en) | 2002-07-29 | 2002-07-29 | Novel method of treatment |
| GB0313801A GB0313801D0 (en) | 2003-06-13 | 2003-06-13 | Novel methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2323268T3 true ES2323268T3 (es) | 2009-07-10 |
Family
ID=31499035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03766343T Expired - Lifetime ES2323268T3 (es) | 2002-07-29 | 2003-07-28 | Formulaciones de liberacion prolongada que contienen lamotrigina. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20050032799A1 (es) |
| EP (1) | EP1524981B1 (es) |
| JP (2) | JP4744142B2 (es) |
| KR (1) | KR100882707B1 (es) |
| CN (1) | CN100363007C (es) |
| AR (1) | AR040709A1 (es) |
| AT (1) | ATE424827T1 (es) |
| AU (1) | AU2003260336C1 (es) |
| BR (1) | BRPI0313148B8 (es) |
| CA (1) | CA2493301A1 (es) |
| CO (1) | CO5680405A2 (es) |
| CY (1) | CY1109119T1 (es) |
| DE (1) | DE60326590D1 (es) |
| DK (1) | DK1524981T3 (es) |
| ES (1) | ES2323268T3 (es) |
| IL (1) | IL166424A (es) |
| IS (1) | IS2681B (es) |
| MA (1) | MA27509A1 (es) |
| MX (1) | MXPA05001243A (es) |
| MY (1) | MY141049A (es) |
| NO (1) | NO334221B1 (es) |
| NZ (1) | NZ537885A (es) |
| PL (1) | PL213565B1 (es) |
| PT (1) | PT1524981E (es) |
| RU (1) | RU2325163C2 (es) |
| SI (1) | SI1524981T1 (es) |
| TW (1) | TWI342213B (es) |
| WO (1) | WO2004012741A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
| DK1524981T3 (da) * | 2002-07-29 | 2009-06-22 | Glaxo Group Ltd | Sammensætninger med vedvarende frigivelse indeholdende lamotrigin |
| EP1686967A4 (en) * | 2003-11-25 | 2012-08-08 | Smithkline Beecham Cork Ltd | CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES |
| WO2006023347A1 (en) * | 2004-08-20 | 2006-03-02 | Alpharma, Inc. | Paroxetine formulations |
| US8058291B2 (en) * | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| WO2008109343A1 (en) * | 2007-03-01 | 2008-09-12 | Memory Pharmaceuticals Corporation | Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate |
| US20090022789A1 (en) * | 2007-07-18 | 2009-01-22 | Supernus Pharmaceuticals, Inc. | Enhanced formulations of lamotrigine |
| WO2009061513A1 (en) * | 2007-11-09 | 2009-05-14 | Thar Pharmaceuticals | Crystalline forms of lamotrigine |
| US20090196924A1 (en) * | 2008-02-04 | 2009-08-06 | Pramod Kharwade | Controlled-release lamotrigine formulations |
| EA201170230A1 (ru) * | 2008-07-18 | 2011-08-30 | Вэлиант Фармасьютикалс Интернешнл | Препарат с модифицированной кинетикой высвобождения и способы его использования |
| US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| JP5885668B2 (ja) | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ， インコーポレイテッド | アマンタジン組成物および使用方法 |
| WO2011086568A1 (en) * | 2010-01-13 | 2011-07-21 | Accutest Research Laboratories (I) Pvt. Ltd | Controlled release composition for lamotrigine |
| MX2013008946A (es) * | 2011-02-03 | 2013-10-25 | Lupin Ltd | Composiciones farmaceuticas orales de bepotastina de liberacion controlada. |
| WO2014159275A1 (en) * | 2013-03-14 | 2014-10-02 | PharmTak, Inc. | Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same |
| CN103920134A (zh) * | 2014-05-08 | 2014-07-16 | 崔韡 | 一种治疗儿童眩晕的缓释片及其制备方法 |
| RU2624229C2 (ru) * | 2015-12-21 | 2017-07-03 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с замедленным высвобождением и способ их получения |
| RU2613192C1 (ru) * | 2016-02-18 | 2017-03-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки клозапина с пролонгированным высвобождением |
| US20200046716A1 (en) * | 2017-02-03 | 2020-02-13 | Jubilant Generics Limited | Lamotrigine suspension dosage form |
| CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
| SG11202003391XA (en) * | 2017-10-27 | 2020-05-28 | Chang Gung Memorial Hospital Linkou | Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof |
| US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
| US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
| EP3784227A4 (en) * | 2018-04-25 | 2022-03-02 | Neurocentria, Inc. | MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES |
| CN114948868B (zh) * | 2021-04-16 | 2023-04-14 | 上海奥科达医药科技股份有限公司 | 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物 |
| CN116942606A (zh) * | 2022-04-18 | 2023-10-27 | 上海奥科达医药科技股份有限公司 | 拉莫三嗪悬浮液和干混悬剂的制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704295A (en) * | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4556552A (en) * | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| JPH0667828B2 (ja) * | 1985-10-09 | 1994-08-31 | 日研化学株式会社 | バルプロ酸ナトリウムの持続性顆粒製剤 |
| US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| US4816262A (en) * | 1986-08-28 | 1989-03-28 | Universite De Montreal | Controlled release tablet |
| GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
| IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane |
| US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| DK0542364T3 (da) * | 1991-11-13 | 1996-03-11 | Glaxo Canada | Anordning til reguleret frigivelse |
| IT1266565B1 (it) * | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
| AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| DE69733081T2 (de) * | 1996-08-23 | 2006-05-11 | Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) | Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen |
| GB9625795D0 (en) * | 1996-12-12 | 1997-01-29 | Smithkline Beecham Plc | Novel treatment |
| US6046716A (en) * | 1996-12-19 | 2000-04-04 | Colorado Microdisplay, Inc. | Display system having electrode modulation to alter a state of an electro-optic layer |
| CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
| GB9726987D0 (en) * | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| AU1238500A (en) * | 1998-11-02 | 2000-05-22 | Alza Corporation | Controlled delivery of active agents |
| GB9930079D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| GB0024517D0 (en) * | 2000-10-06 | 2000-11-22 | Glaxo Group Ltd | Use of medicaments |
| DE10224170A1 (de) * | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| DK1524981T3 (da) * | 2002-07-29 | 2009-06-22 | Glaxo Group Ltd | Sammensætninger med vedvarende frigivelse indeholdende lamotrigin |
-
2003
- 2003-07-28 DK DK03766343T patent/DK1524981T3/da active
- 2003-07-28 MX MXPA05001243A patent/MXPA05001243A/es active IP Right Grant
- 2003-07-28 KR KR1020057001633A patent/KR100882707B1/ko not_active Expired - Lifetime
- 2003-07-28 BR BRPI0313148A patent/BRPI0313148B8/pt not_active IP Right Cessation
- 2003-07-28 AT AT03766343T patent/ATE424827T1/de active
- 2003-07-28 CA CA002493301A patent/CA2493301A1/en not_active Withdrawn
- 2003-07-28 SI SI200331585T patent/SI1524981T1/sl unknown
- 2003-07-28 WO PCT/EP2003/008368 patent/WO2004012741A1/en not_active Ceased
- 2003-07-28 DE DE60326590T patent/DE60326590D1/de not_active Expired - Lifetime
- 2003-07-28 TW TW092120477A patent/TWI342213B/zh not_active IP Right Cessation
- 2003-07-28 RU RU2005105353/14A patent/RU2325163C2/ru active
- 2003-07-28 JP JP2004525362A patent/JP4744142B2/ja not_active Expired - Lifetime
- 2003-07-28 NZ NZ537885A patent/NZ537885A/en not_active IP Right Cessation
- 2003-07-28 AU AU2003260336A patent/AU2003260336C1/en not_active Expired
- 2003-07-28 EP EP03766343A patent/EP1524981B1/en not_active Expired - Lifetime
- 2003-07-28 AR AR20030102702A patent/AR040709A1/es not_active Application Discontinuation
- 2003-07-28 MY MYPI20032831A patent/MY141049A/en unknown
- 2003-07-28 PT PT03766343T patent/PT1524981E/pt unknown
- 2003-07-28 PL PL374982A patent/PL213565B1/pl unknown
- 2003-07-28 CN CNB038223716A patent/CN100363007C/zh not_active Expired - Lifetime
- 2003-07-28 ES ES03766343T patent/ES2323268T3/es not_active Expired - Lifetime
- 2003-07-29 US US10/629,177 patent/US20050032799A1/en not_active Abandoned
-
2005
- 2005-01-20 IL IL166424A patent/IL166424A/en unknown
- 2005-01-28 CO CO05007005A patent/CO5680405A2/es not_active Application Discontinuation
- 2005-01-28 MA MA28074A patent/MA27509A1/fr unknown
- 2005-02-22 NO NO20050948A patent/NO334221B1/no not_active IP Right Cessation
- 2005-02-23 IS IS7707A patent/IS2681B/is unknown
-
2009
- 2009-05-29 CY CY20091100580T patent/CY1109119T1/el unknown
-
2010
- 2010-10-15 JP JP2010232745A patent/JP2011057683A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034757A1 (es) | Formulacion farmaceutica que comprende un inhibidor de bomba de protones y antiacidos | |
| MY141049A (en) | Sustained release formulations comprising lamotrigine | |
| CR20110373A (es) | Preparación de liberación controlada (divisional solicitud n° 10284) | |
| WO2004108067A3 (en) | Programmed drug delivery system | |
| AR099567A2 (es) | Formulación de tableta revestida que comprende saxagliptina y método de preparación | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| ATE476957T1 (de) | Pharmazeutische zusammensetzung auf fondantbasis | |
| DE602004014962D1 (de) | Vielzweckmaske | |
| WO2004096317A3 (en) | Flush catheter with flow directing sheath | |
| NZ503432A (en) | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function | |
| CR8481A (es) | Derivados de triazol como antagonistas de la vasopresina | |
| MX2007003327A (es) | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. | |
| IT1318430B1 (it) | Dispositivo per l'umidificazione passiva di pazienti tracheostomizzati o intubati. | |
| CR11263A (es) | COMPUESTOS NOVEDOSOS QUE POSEEN ACTIVIDAD INNHIBITORIA CONTRA TRANSPORTADOR DE GLUCOSA DEPENDIENTE DE SODIO (Solicitud divisional) | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ITMI20020514A0 (it) | Sistema terapeutico per il rilascio controllato di uno o piu' principi attivi | |
| UY27767A1 (es) | Heterociclos bicíclicos, medicamentos que contienen estos compuestos, su empleo, y procedimientos para su preparación. | |
| BR0305708A (pt) | Derivados de benzimidazol para o tratamento de disfunção sexual | |
| ES2422081T3 (es) | Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales | |
| ATE465725T1 (de) | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege | |
| DE60321801D1 (de) | Sphäroide, deren herstellungsverfahren und sphäroidenhaltige arzneimittel | |
| CA2236553A1 (en) | Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy | |
| DK1105141T3 (da) | Phosphatidylcholin som et medikament med slimhindebeskyttende virkning | |
| WO2007030387A3 (en) | Outer and inner ear drying system | |
| DE50204203D1 (de) | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes |